Dr. Melissa V. Rewolinski is a proven R&D executive, scientific leader, and board member whose distinguished 30-year career in the pharmaceutical and biotechnology sectors has been defined by innovation, operational excellence, and a steadfast commitment to advancing human health. As Principal of MVR Consulting, Inc., she brings a wealth of experience to emerging biotech and pharmaceutical companies, offering strategic counsel that bridges scientific insight with business acumen. Her journey from an organic chemist to a boardroom leader reflects not only her technical mastery but also her enduring belief in the power of collaboration, discipline, and vision-driven leadership.
Over three decades, Dr. Rewolinski has guided organizations through the complex landscape of drug discovery, development, and commercialization. Her expertise spans every stage of the pharmaceutical lifecycle—from preclinical research and IND-enabling studies to global commercialization and lifecycle management. Known for her ability to connect scientific discovery with strategic decision-making, she has played a pivotal role in bringing groundbreaking therapies to patients around the world. Her influence reaches across continents, with professional engagements in the United States, Europe, and Asia, and her leadership has been instrumental in the success of numerous R&D programs and partnerships.
Dr. Rewolinski’s early foundation in chemistry was forged at Rice University, where she earned both her Bachelor of Science and Ph.D. in Organic Chemistry. With a GPA that reflected her precision and intellectual rigor, she developed an early fascination with the chemistry of life—how molecular structures could be harnessed to alleviate disease and improve quality of life. This passion became the guiding thread of her career, influencing every role she would later hold in the industry. Her doctoral work in synthetic organic chemistry provided the technical grounding that would later inform her approach to R&D operations, regulatory compliance, and commercialization.
Her professional career began at Pharmacia & Upjohn, where she gained post-doctoral experience in medicinal chemistry before joining Agouron Pharmaceuticals. At Agouron/Pfizer, she quickly ascended into leadership, serving as Director within Chemical Research and Development. She managed multidisciplinary teams responsible for drug substance and product development across several therapeutic areas, including HIV and oncology. Her ability to unify scientists, regulatory experts, and operations teams around a shared goal distinguished her as both a strategist and a people-centered leader—one who could translate complex science into actionable results.
Following her tenure at Pfizer, Dr. Rewolinski joined Amira Pharmaceuticals, where she played a key role in delivering multiple compounds into clinical development within a remarkably short timeframe. Her talent for integrating R&D, clinical operations, and regulatory strategy helped accelerate discovery pipelines and strengthen the company’s position within the competitive biotech landscape. At Amira, she cultivated a reputation for fostering innovation under pressure, demonstrating that strategic thinking and scientific creativity could coexist seamlessly in pursuit of breakthrough therapies.
Her defining decade came at Intercept Pharmaceuticals, where she rose to the position of Senior Vice President and Head of R&D Operations. In this executive role, she oversaw all facets of pharmaceutical R&D. Under her leadership, Intercept achieved global commercialization of Ocaliva® (obeticholic acid), the first approved therapy for Primary Biliary Cholangitis (PBC) in over twenty years. Dr. Rewolinski’s guidance was instrumental in bringing this treatment to patients across more than twenty countries, cementing her legacy as a scientific leader with both vision and operational precision. Her contributions extended beyond the laboratory and boardroom—she also served as a bridge between cultures and organizations through international alliances, including a partnerships in Japan and China.
Today, as Principal of MVR Consulting, Inc., Dr. Rewolinski advises early-stage and mid-size biotechnology companies in R&D operations, business strategy, and risk management. Her firm provides vital support to organizations navigating the intricacies of drug development, helping founders and executives make informed, forward-looking decisions. She has partnered with companies such as Federation Bio, Zehna Therapeutics, and Xontogeny, providing insight that ensures alignment between science, strategy, and investor expectations. Her consultancy is a reflection of her lifelong commitment to elevating standards in pharmaceutical development while empowering the next generation of leaders in the life sciences industry.
Beyond her consulting work, Dr. Rewolinski continues to shape the industry from the boardroom. She has served on the Boards of Lannett Company (NYSE), Arbutus Biopharma (NASDAQ), and the American Type Culture Collection (ATCC). Her governance experience spans audit, compensation, science and technology, and nominating committees—demonstrating her fluency in both financial oversight and scientific integrity. At ATCC, she will serve as Chair-elect beginning in 2026, underscoring the trust her peers place in her leadership and vision. Her contributions in these roles highlight her holistic understanding of both business governance and scientific excellence, a rare combination that distinguishes her among board members in the life sciences sector.
Throughout her career, Dr. Rewolinski has cultivated a global perspective. Her professional engagements and collaborations have taken her across Italy, Portugal, Germany, Ireland, Japan, China, the Netherlands, and Denmark. This international exposure has deepened her appreciation for cultural diversity in scientific innovation and has informed her leadership philosophy: that success in life sciences is achieved through the integration of global insight, ethical governance, and a shared purpose to serve patients. Her global mindset also strengthens her ability to navigate complex regulatory environments, cross-border partnerships, and multinational R&D operations.
Beyond her professional achievements, Dr. Rewolinski is deeply rooted in her personal values. She is family-centric, passionate about health and wellness, and devoted to lifelong learning. Her love for travel, fitness, and the outdoors reflects her belief that balance and curiosity fuel great leadership. Those who know her best describe her as a leader who listens deeply, acts decisively, and inspires confidence through authenticity and humility. Whether mentoring emerging scientists or serving on high-level committees, she brings a sense of purpose, warmth, and precision to every endeavor.
Dr. Rewolinski’s story is one of resilience, intellect, and innovation. She has not only shaped the development of life-saving therapies but also cultivated environments where science and strategy thrive in harmony. Her legacy continues to grow—both as a mentor to the next generation of biotech leaders and as a board member shaping the future of healthcare innovation. Through her work, she exemplifies what it means to lead with integrity, clarity, and courage in a field where lives depend on thoughtful, principled decision-making.
Character:
Dr. Rewolinski is a leader defined by integrity, compassion, and an unwavering commitment to excellence. She consistently places the mission of improving patient lives above all else, guiding her teams and colleagues with authenticity and respect. Her ethical compass and dedication to responsible innovation make her a trusted advisor and a stabilizing force in high-stakes environments.
Knowledge:
With a Ph.D. in Organic Chemistry and decades of executive experience, Dr. Rewolinski brings deep scientific and operational knowledge to every organization she touches. Her understanding of drug development—from molecular design to global commercialization—positions her as a thought leader in the life sciences. She continuously applies this expertise to help companies translate scientific potential into sustainable success.
Strategic:
Known for her ability to connect data-driven insight with visionary foresight, Dr. Rewolinski excels at long-range planning and risk management. She has a rare talent for simplifying complexity, aligning diverse stakeholders, and executing strategic initiatives that drive measurable results. Her board and consulting leadership reflect a consistent ability to anticipate challenges, adapt to change, and chart a clear path forward.
Communication:
A compelling communicator and collaborator, Dr. Rewolinski builds trust through transparency and clarity. She bridges the gap between science and strategy, translating intricate technical details into narratives that inspire action and understanding. Her leadership style encourages dialogue, empowers teams, and ensures alignment across scientific, operational, and executive functions.
